Russian regulators nix Abbott's M&A plans

Abbott Laboratories ($ABT) made a bid to acquire Russian vaccine outfit Petrovax, but the country's Federal Anti-Monopoly Service scuttled its plan, Reuters reports. The rebuff comes as Abbott is rumored to be eyeing a buyout of Brazil's Aché Laboratorios Farmaceuticos, worth up to $5 billion. The company has focused on medical devices, diagnostics, nutrition and generics since its Jan. 1 spinoff of proprietary pharma, but it may be eyeing entré into the emerging markets drug business. Article | More from FiercePharma

Suggested Articles

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions.

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.